Selecting patients with young-onset colorectal cancer for mismatch repair gene analysis

British Journal of Surgery

Volumn 94, Issue 12, 2007, Pages 1567-1571

  Walker, M ^a   O'Sullivan, B ^a   Perakath, B ^b   Taniere, P ^a   Cruger, D ^c   Morton, D ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c Velije Hospital   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COLORECTAL CANCER; EARLY CANCER; FEMALE; GENE MUTATION; GENETIC SCREENING; HIGH RISK BEHAVIOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; FEMALE; GERM-LINE MUTATION; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PATIENT SELECTION; PEDIGREE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 37249077632     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.5822     Document Type: Article

References (17)

1. Nagy R, Sweet K, Eng C. Highly penetrant heriditary cancer syndromes. Oncogene 2004; 23: 6445-6470.
2. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004; 4: 769-780.
3. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-834.
4. Katballe N, Christensen M, Wikman FP, Orntoft TF, Laurberg S. Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients. Gut 2002; 50: 43-51.
5. Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005; 23: 6524-6532.
6. Farrington SM, Lin-Goerke J, Ling J, Wang Y, Burczak JD, Robbins DJ et al. Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls. Am J Hum Genet 1998; 63: 749-759.
7. Vasen HFA, Watson P, Mecklin J-P, Lynch HT. New clinical criteria for hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-1456.
8. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268.
9. Muta H, Noguchi M, Perucho M, Ushio K, Sugihara K, Ochiai A et al. Clinical implications of microsatellite instability in colorectal cancers. Cancer 1996; 77: 265-270.
10. Hampel H, Frankel W, Martin E, Arnold M, Khanduja K, Kuebler P et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-1860.
11. Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293: 1986-1994.
12. Watson P, Lynch HT. Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 2001; 1: 57-60.
13. Kievit W, de Bruin JH, Adang EM, Ligtenberg MJ, Nagengast FM, van Krieken JH et al. Current clinical strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet 2004; 65: 308-316.
14. de Jong AE, van Puijenbroek M, Hendriks Y, Tops C, Wijnen J, Ausems MG et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 972-980.
15. Kakar S, Burgart LJ, Thibodeau SN, Rabe KG, Petersen GM, Goldberg RM et al. Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age. Cancer 2003; 97: 1421-1427.
16. Grover S, Stoffel EM, Bussone L, Tschoegi E, Syngal S. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2004; 2: 813-819.
17. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24: 2359-2367.